Bicara Therapeutics Inc. financial data

Symbol
BCAX on Nasdaq
Location
245 Main Street, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.28K %
Debt-to-equity 4.33 %
Return On Equity -27.2 % +97%
Return On Assets -26 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.8M shares +0.67%
Common Stock, Shares, Outstanding 54.6M shares +0.37%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 54.6M shares +401%
Weighted Average Number of Shares Outstanding, Diluted 54.6M shares +401%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 112M USD +108%
General and Administrative Expense 29.1M USD +61.7%
Operating Income (Loss) -141M USD -97.2%
Nonoperating Income (Expense) 19.9M USD +39.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -121M USD -108%
Income Tax Expense (Benefit) 343K USD
Net Income (Loss) Attributable to Parent -122M USD -104%
Earnings Per Share, Basic 33 USD/shares +58.1%
Earnings Per Share, Diluted 33 USD/shares +58.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 172M USD -67%
Assets, Current 297M USD -43%
Property, Plant and Equipment, Net 135K USD +3.85%
Operating Lease, Right-of-Use Asset 1.97M USD +376%
Other Assets, Noncurrent 7.8M USD +269%
Assets 425M USD -19%
Employee-related Liabilities, Current 3.99M USD +121%
Accrued Liabilities, Current 12.9M USD +59.9%
Liabilities, Current 21M USD +45.2%
Operating Lease, Liability, Noncurrent 880K USD +542%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 21.9M USD +49.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -136K USD
Retained Earnings (Accumulated Deficit) -322M USD -60.7%
Stockholders' Equity Attributable to Parent 403M USD -21%
Liabilities and Equity 425M USD -19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.1M USD -92.7%
Net Cash Provided by (Used in) Financing Activities 460K USD +236%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 54.6M shares +0.34%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -27.6M USD -92.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 172M USD -67%
Deferred Tax Assets, Valuation Allowance 59M USD +56.5%
Deferred Tax Assets, Gross 59.2M USD +56.3%
Operating Lease, Liability 738K USD
Depreciation 19K USD +46.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.5M USD -109%
Lessee, Operating Lease, Liability, to be Paid 771K USD
Operating Lease, Liability, Current 1.1M USD +256%
Lessee, Operating Lease, Liability, to be Paid, Year Two 132K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 639K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33K USD
Deferred Tax Assets, Operating Loss Carryforwards 25.3M USD +16.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 724M USD +2.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 13.7M USD +77.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%